查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1520590

2024-2032 年阿霉素市场报告（按应用、配销通路和地区）

Doxorubicin Market Report by Application, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球阿霉素市场规模达13亿美元。

阿霉素（DOX）是一种用于治疗癌症的化疗过程中的仿製药。它以注射液或冷冻干燥粉末形式经由週边插入中心静脉导管（PICC）或中心静脉导管（CVC）进行静脉注射。静脉注射后，DOX 被酵素迅速消除，并在血浆中水解降解。它用于治疗多种类型的癌症，包括乳腺癌、膀胱癌、卡波西氏肉瘤、淋巴瘤、肾母细胞瘤、非何杰金氏淋巴瘤和急性淋巴细胞白血病。

阿霉素市场趋势：

癌症盛行率的增加主要推动了全球阿霉素市场的发展。这导致越来越多地使用 DOX 与其他化疗药物合併治疗多种癌症。除此之外，对微创 (MI) 外科手术的需求不断增长，以及无法接受重大手术的老年人口不断增加，导致人们越来越倾向于将 DOX 作为癌症治疗疗法的一部分。各国政府也正在实施支持临床肿瘤学技术进步的倡议，包括无静脉注射治疗和用于晶片生化分析的数位微流控技术。他们也正在进行提高癌症治疗意识的计画。因此，对 DOX 的需求显着增加。此外，研究人员正在花费大量资金进行临床试验，以开发技术先进的 DOX 配方。此外，越来越多的併购以及先进形式 DOX 临床试验的合作伙伴关係预计将为未来几年的市场创造积极的前景。

本报告回答的关键问题：

  • 迄今为止，全球阿霉素市场表现如何，未来几年将如何表现？
  • COVID-19 对全球阿霉素市场有何影响？
  • 主要区域市场有哪些？
  • 基于应用程式的市场区隔是什么？
  • 基于配销通路的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球阿霉素市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球阿霉素市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按应用

  • 乳癌
    • 市场走向
    • 市场预测
  • 卵巢癌
    • 市场走向
    • 市场预测
  • 多发骨髓瘤
    • 市场走向
    • 市场预测
  • 卡波西氏肉瘤
    • 市场走向
    • 市场预测
  • 白血病
    • 市场走向
    • 市场预测
  • 骨肉瘤
    • 市场走向
    • 市场预测
  • 子宫内膜癌
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按配销通路

  • 医院和零售药房
    • 市场走向
    • 市场预测
  • 网上商店
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
    • Baxter International Inc.
    • Cadila Pharmaceuticals
    • Cipla Inc.
    • Hikma Pharmaceuticals PLC
    • Meiji Holdings Co. Ltd.
    • Novartis AG
    • Pfizer Inc.
Product Code: SR112024A5677

The global doxorubicin market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.33% during 2024-2032.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, Wilms' tumor, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global doxorubicin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application and distribution channel.

Breakup by Application:

Breast Cancer

Ovarian Cancer

Multiple Myeloma

Kaposi Sarcoma

Leukemia

Bone Sarcoma

Endometrial Cancer

Others

Breakup by Distribution Channel:

Hospital and Retail Pharmacies

Online Stores

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report:

  • How has the global doxorubicin market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global doxorubicin market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global doxorubicin market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Doxorubicin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Kaposi Sarcoma
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Leukemia
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Bone Sarcoma
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Endometrial Cancer
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital and Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Online Stores
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Baxter International Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Cadila Pharmaceuticals
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Cipla Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Hikma Pharmaceuticals PLC
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Meiji Holdings Co. Ltd.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Novartis AG
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Pfizer Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
  • Figure 2: Global: Doxorubicin Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2023
  • Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2023
  • Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Global: Doxorubicin Industry: SWOT Analysis
  • Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
  • Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Doxorubicin Market: Competitive Structure
  • Table 6: Global: Doxorubicin Market: Key Players